ClinicalTrials.gg
CompletedNCT00225979Updated Apr 11, 2012

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

A Phase 3 interventional study of Octreotide LAR in Acromegaly, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
6th of 25
100 · median 56
Started
2002
with 2 others
Phase 3
12 of 25
1 open now
Registered
5th of 25
by date
Lead sponsor
5 of 25
Novartis Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one is the 6th largest by enrollment, is one of 3 that started in 2002, is one of 12 in phase 3, and was the 5th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly. The objective of this study is to assess the safety and efficacy of long-acting repeatable formulation of octreotide and to compare it to the safety and efficacy of surgery in patients with acromegaly who have not had any previous treatment for acromegaly.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • Untreated
  • Newly diagnosed
  • Octreotide LAR
  • Pituitary surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed or previously untreated acromegalic patients
  • Lack of suppression of GH nadir to \<1.0 µg/L, after oral administration of 75 g of glucose (OGTT)
  • IGF-I levels above the , i.e. 97th percentile (adjusted for age and gender)

Exclusion criteria

Exclusion Criteria:

  • Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass
  • No evidence of pituitary adenoma on Magnetic Resonance Imaging (MRI)
  • Symptomatic cholelithiasis

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    SMS995

    Drug: Octreotide LAR

Interventions

06

What researchers measure

Primary outcomes

  1. Mean GH and IGF-I at baseline, week 12, 24 and 48

Secondary outcomes

  1. Tumor volume at baseline, week 24 and 48

  2. Signs and symptoms of acromegaly at baseline, week 12, 24 and 48

  3. Quality of life and sleep apnea at baseline, week 12, 24 and 48

  4. Safety and tolerability at any time on treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2005
First posted
Sep 26, 2005
Start
Nov 2002
Primary completionActual
Mar 2005
CompletionActual
Mar 2005
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00225979
Responsible party
Sponsor
First posted
Sep 26, 2005
Start date
Nov 2002
Primary completion
Mar 2005
Completion
Mar 2005
Last update
Apr 11, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion